• 1.

    Goldsmith DJ. Pro: Should we correct vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms? Nephrol Dial Transplant 2016; 31:698705.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Goldsmith D, et al.. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant 2015; 30:698700.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Pfeffer MA, et al.. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:20192032.

  • 4.

    EVOLVE Trial Investigators , et al.. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:24822494.

  • 5.

    Cunningham J, et al.. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:17931800.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Parfrey PS, et al.. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial. J Clin Endocrinol Metab 2013; 98:48344844.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Reams BD, et al.. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: A retrospective new-user cohort design. BMC Nephrol 2015; 16:175.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Evenepoel P, et al.. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 2014; 14:25452555.

    • Crossref
    • Search Google Scholar
    • Export Citation

The Case for Earlier/Targeted Treatment of Hyperparathyroidism with Cinacalcet: Calcimimetics Have Much to Offer the “Right” Patient

  • 1 Professor David Goldsmith, MA, MB BChir, FRCP (Lond), FRCP (Ed), FASN, is a consultant nephrologist, Guy’s and St Thomas’ Hospitals, and professor, Cardiovascular and Cell Sciences Institute, St George’s University of London.
Restricted access
Save